Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients - Archive ouverte HAL Access content directly
Journal Articles American Journal of Ophthalmology Year : 2022

Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients

, , , , , (1) , , , , , , , , , , , , , , ,
1
Georgina Maalouf
Anaïs Andrillon
Mathilde Leclercq
  • Function : Author
Pascal Sève
  • Function : Author
Philip Bielefeld
Thomas Sené
  • Function : Author
Cherif Titah
  • Function : Author
Thomas Moulinet
Bénédicte Rouvière
Damien Sène
Anne-Claire Desbois
  • Function : Author
Fanny Domont
  • Function : Author
Sara Touhami
  • Function : Author
Thomas Thibault
  • Function : Author
Carolla El Chamieh
Patrice Cacoub
  • Function : Author
Laurent Kodjikian
  • Function : Author
Lucie Biard
Bahram Bodaghi
  • Function : Author
David Saadoun
  • Function : Correspondent author

Abstract

Purpose: To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA). Design: Observational retrospective multicenter study. Methods: A total of 330 patients (median age, 36 years; interquartile range, 27-54), 45.2% men) with sight-threatening NIU (ie, retinal vasculitis and/or macular edema) treated with anti-tumor necrosis factor [TNF]-α agents (IFX intravenously at 5 mg/kg at weeks 0, 2, 6, and every 4 to 6 weeks or ADA subcutaneously at 80 mg, then 40 mg every 2 weeks). Data were obtained retrospectively from patients' medical records. Main outcome measures were relapse rate, complete response of NIU, corticosteroid sparing effect, and safety. Results: Main etiologies of uveitis included Behçet disease (27%), idiopathic juvenile arthritis (5.8%), and sarcoidosis (5.5%). The estimated relapse rate at 6 months after introduction of biological agents was 13% (95% CI = 0.009-0.16). IFX was associated with less relapse risk than ADA (hazard ratio [HR] = 0.52, 95% CI = 0.36- 0.77, P = .001). ADA and IFX were comparable in terms of complete response rate of NIU as well as corticosteroid-sparing effect. Behçet disease was associated with higher odds of complete response (HR = 2.04, 95% CI = 1.16 -3.60, P = .01] and lower relapse rate (HR = 0.53, 95% CI = 0.33-0.85, P = .009) than other causes of NIU with anti-TNF-α agents. Conclusions: In sight-threatening NIU, IFX seems to be associated with a lower relapse rate than ADA.
Not file

Dates and versions

hal-03727497 , version 1 (19-07-2022)

Licence

Copyright

Identifiers

Cite

Georgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, Pascal Sève, Philip Bielefeld, et al.. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. American Journal of Ophthalmology, 2022, 238, pp.173-180. ⟨10.1016/j.ajo.2022.02.002⟩. ⟨hal-03727497⟩
18 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More